- Home
- SM vs KNSA Comparison
SM vs KNSA Comparison
Compare SM & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SM
- KNSA
- Stock Information
- Founded
- SM 1908
- KNSA 2015
- Country
- SM United States
- KNSA United Kingdom
- Employees
- SM N/A
- KNSA N/A
- Industry
- SM Oil & Gas Production
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- SM Energy
- KNSA Health Care
- Exchange
- SM Nasdaq
- KNSA Nasdaq
- Market Cap
- SM 3.0B
- KNSA 2.6B
- IPO Year
- SM 1992
- KNSA 2018
- Fundamental
- Price
- SM $25.24
- KNSA $38.51
- Analyst Decision
- SM Hold
- KNSA Strong Buy
- Analyst Count
- SM 11
- KNSA 7
- Target Price
- SM $42.44
- KNSA $44.00
- AVG Volume (30 Days)
- SM 2.2M
- KNSA 392.4K
- Earning Date
- SM 10-30-2025
- KNSA 10-28-2025
- Dividend Yield
- SM 3.18%
- KNSA N/A
- EPS Growth
- SM 1.83
- KNSA N/A
- EPS
- SM 7.07
- KNSA 0.07
- Revenue
- SM $3,002,621,000.00
- KNSA $529,332,000.00
- Revenue This Year
- SM $33.13
- KNSA $37.21
- Revenue Next Year
- SM N/A
- KNSA $12.07
- P/E Ratio
- SM $3.56
- KNSA $582.26
- Revenue Growth
- SM 27.02
- KNSA 56.18
- 52 Week Low
- SM $19.67
- KNSA $17.82
- 52 Week High
- SM $46.42
- KNSA $39.12
- Technical
- Relative Strength Index (RSI)
- SM 42.20
- KNSA 64.65
- Support Level
- SM $24.64
- KNSA $37.69
- Resistance Level
- SM $26.41
- KNSA $38.83
- Average True Range (ATR)
- SM 1.11
- KNSA 0.95
- MACD
- SM -0.15
- KNSA 0.00
- Stochastic Oscillator
- SM 9.73
- KNSA 79.11
About SM SM Energy Company
SM Energy Co is an independent energy company engaged in the acquisition, exploration, development, and production of oil, gas, and NGLs in Texas and Utah. Its portfolio is comprised of assets in the Midland Basin of West Texas, the Maverick Basin of South Texas, and the Uinta Basin of northeastern Utah.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.